Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.

To investigate whether human immunodeficiency virus type 1 pol gene mutations are selected during prolonged 2',3'-dideoxycytidine (ddC) therapy, we used the polymerase chain reaction to amplify a portion of the reverse transcriptase segment of the pol gene from the peripheral blood mononuclear cell...

Deskribapen osoa

Xehetasun bibliografikoak

Argitaratua izan da:	Antimicrob Agents Chemother
Egile Nagusiak:	Fitzgibbon, J E, Howell, R M, Haberzettl, C A, Sperber, S J, Gocke, D J, Dubin, D T
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology (ASM) 1992
Gaiak:	Research Article
Sarrera elektronikoa:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC189244/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1317143/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.36.1.153
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!